This bean – also known as the hyacinth, Egyptian kidney, and Indian bean – is a legume that contains a protein that can "trap" and neutralize certain viruses, essentially giving it antiviral properties. This protein, FRIL, is also inherently stable when the legume is converted into a powder and turned into chewing gum.
And, impressively, 40 mg of a two-gram bean gum tablet could reduce viral loads by more than 95%. This was not a surprise for researchers, though, as it closely mirrors the team's results from an earlier study testing a gum antiviral for COVID-19. That is now in its clinical trial stages.
"Lack of [a] herpes simplex virus (HSV) vaccine, low vaccination rates of Influenza viruses, waning immunity and viral transmission after vaccination underscore the need to reduce viral loads at their transmission sites," the team noted, adding why they're focused on the mouth, not the nose like other avenues of drug delivery research. "Oral virus transmission is several orders of magnitude higher than nasal transmission."
As well as eying off a clinical trial for this novel gum, the researchers are now looking at tackling avian influenza, the H5N1 virus.
“Controlling transmission of viruses continues to be major global challenge," said researcher Henry Daniell. "A broad spectrum antiviral protein (FRIL) present in a natural food product (bean powder) to neutralize not only human flu viruses but also avian (bird) flu is a timely innovation to prevent their infection and transmission.
"These observations augur well for evaluating bean gum in human clinical studies to minimize virus infection/transmission," he added.
The research was published in the journal Molecular Therapy.
No comments:
Post a Comment